Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
national blog main
9
×
startups
9
×
life sciences
san francisco blog main
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san francisco top stories
clinical trials
deals
san diego blog main
san diego top stories
detroit blog main
detroit top stories
fda
investing
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
indiana blog main
indiana top stories
medical device
national
nonalcoholic steatohepatitis
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
acute myeloid leukemia
biotech ipos
boston
bristol-myers squibb
What
biotech
9
×
new
attention
drug
roundup
startup
therapeutics
annual
based
cancer
control
developing
ipo
make
markets
medical
medicines
million
public
raised
research
today
way
week
according
ahead
aiming
aims
akcea
alzheimer’s
ambien
ambys
american
analysis
ann
approach
arbor
asco
assessed
athena
Language
unset
Current search:
biotech
×
startups
×
" national blog main "
×
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
5 years ago
Celsee Charts Expansion Plans as Single-Cell Analysis Demand Grows
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More